Connective tissue diseases and pregnancy

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Saar, P ^a   Hermann, W ^a   Muller Ladner U ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ILOPROST; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LA ANTIBODY; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; RO ANTIBODY; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BREAST FEEDING; CONGENITAL HEART BLOCK; CONNECTIVE TISSUE DISEASE; CREATININE CLEARANCE; DELIVERY; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EMBRYOTOXICITY; FETUS ELECTROCARDIOGRAPHY; GYNECOLOGY; HEMOSTASIS; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; LUNG FUNCTION TEST; LUPUS ERYTHEMATOSUS; MEDICAL DECISION MAKING; MEDICAL EXAMINATION; MUTAGENICITY; NEONATOLOGY; OBSTETRICS; PATIENT COUNSELING; PATIENT MONITORING; PERINATAL PERIOD; PREGNANCY; PREMATURITY; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; PULMONARY HYPERTENSION; RHEUMATOLOGY; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TERATOGENICITY;

CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; PATIENT CARE TEAM; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE;

EID: 33749012253     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel288     Document Type: Article

References (16)

1. Molad Y, Borkowski T, Monselise A et al. Maternal and fetal outcome of lupus pregnancy: A prospective study of 29 pregnancies. Lupus 2005;14:145-51.
2. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
3. Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004;50:3941-6.
4. Chakravarty EF, Colon I, Lengen ES et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
5. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005;35:112-21.
6. Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus 2004;13:746-50.
7. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24.
8. Gordon P, Rosenthal F, Simpson JM et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004;31:2480-7.
9. Kamel R, Eftekhari P, Clancy R, Buyon JP, Hoebeke J. Autoantibodies against the serotoninergic 5-HT(4) receptor and congenital heart block: a reassessment. J Autoimmun 2005;25:72-6.
10. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: A study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004;50:3187-94.
11. Yang CH, Chen JY, Lee SC, Luo SF. Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti-Sjogren's syndrome A/Ro antibodiy. J Microbiol Immunol Infect 2005;38:365-9.
12. Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Homberger LK. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004;110:1542-8.
13. Bizarro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalance and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005;129:61-8.
14. Reber G, de Moerloose P. Anti-beta2-glyoprotein I antibodies - when and how should they be measured? Thromb Res 2004;114:527-31.
15. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;18:CD002859.
16. Elliot CA, Stewart P, Webster VJ et al. The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension. Eur Respir J 2005;26:168-73.